Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649

被引：0

作者：

Wyrwicz, L. S. ^{[1
]}

Shitara, K. ^{[2
]}

Moehler, M. ^{[3
]}

Ajani, J. A. ^{[4
]}

Shen, L. ^{[5
]}

Garrido, M. ^{[6
]}

Gallardo Araneda, C. E. ^{[7
]}

Yamaguchi, K. ^{[8
]}

Cleary, J. ^{[9
]}

Elimova, E. ^{[10
]}

Bruges Maya, R. ^{[11
]}

Karamouzis, M. V. ^{[12
]}

Skoczylas, T. ^{[13
]}

Bragagnoli, A. C. ^{[14
]}

Liu, T. ^{[15
]}

Tehfe, M. ^{[16
]}

Feeney, K. ^{[17
,18
]}

Wang, R. ^{[19
]}

Zhang, J. ^{[20
]}

Janjigian, Y. Y. ^{[21
,22
]}

机构：

[1] Narodowy Instytut Onkol, Dept Radiotherapy & Oncol, Klin Onkol & Radioterapii, Warsaw, Poland

[2] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[3] Johannes Gutenberg Univ Clin, Dept Med, Mainz, Germany

[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[5] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res Minist Educ, Dept Gastrointestinal Oncol, Beijing, Peoples R China

[6] Pontificia Univ Catolica, Hematooncol Dept, Clin San Carlos de Apoquindo, Santiago, Chile

[7] Fdn Arturo Lopez Perez, Dept Med Oncol, Providencia, Chile

[8] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan

[9] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[10] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[11] Inst Nacl Cancerol ESE, Oncol Clin, Bogota, Colombia

[12] Laiko Gen Hosp Athens, Dept Biol Chem, Athens, Greece

[13] Med Univ Lublin, Dept Gen Surg, Klin Chirurg Ogolnej Gastroenterologicznej & No 2, Lublin, Poland

[14] Fundacao Pio Xii Hosp Canc Barretos, GI Canc, Barretos, Brazil

[15] Fudan Univ, Zhongshan Hosp, Oncol Dept, Shanghai, Peoples R China

[16] Ctr Hosp Univ Montreal, Oncol Ctr, Hematooncol Dept, Montreal, PQ, Canada

[17] Notre Dame Univ, Dept Canc Serv, Murdoch, WA, Australia

[18] Edith Cowan Univ, Murdoch, WA, Australia

[19] Bristol Myers Squibb, Oncol Precis Med, Princeton, NJ USA

[20] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[21] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[22] Weill Cornell Med Coll, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.333

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

419P

引用

页码：S169 / S170

页数：2

共 50 条

[31] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Xu, R-H.
Oh, D-Y.
Kato, K.
Arkenau, H-T.
Tabernero, J.
Cruz-Correa, M.
Zimina, A. V.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Pazo Cid, R. A.
Li, L.
Xu, Y.
McHenry, M. B.
Yang, S.
Moehler, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
[32] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Xu, R-H.
Oh, D-Y.
Kato, K.
Arkenau, T.
Tabernero, J.
Cruz-Correa, M.
Zimina, A.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Cid, R. A. Pazo
Li, L.
Xu, Y.
McHenry, M. B.
Yang, S.
Moehler, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
[33] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
Greil, R.
Chau, I
Doki, Y.
Ajani, J. A.
Xu, J.
Wyrwicz, L.
Motoyama, S.
Ogata, T.
Kawakami, H.
Hsu, C. -H
Adenis, A.
el Hajbi, F.
Di Bartolomeo, M.
Braghiroli, Ignez M.
Holtved, E.
Xynos, I
Liu, X.
Lei, M.
Kondo, K.
Kato, K.
Kitagawa, Y.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
[34] Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO plus chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC)
Chau, Ian
Barzi, Afsaneh
Zhang, Ying
You, Min
Bertwistle, David
Davis, Catherine
Chen, Clara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 295 - 295
[35] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
Chau, Ian
Doki, Yuichiro
Ajani, Jaffer A.
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Freitas Melro Braghiroli, Maria Ignez
Holtved, Eva
Xynos, Ioannis
Liu, Xuan
Lei, Ming
Kondo, Kaoru
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
[36] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)
Moehler, M.
Wyrwicz, L.
Chen, C.
Davenport, E.
Wang, J.
Nathani, R.
Kondo, K.
Elimova, E.
ANNALS OF ONCOLOGY, 2023, 34 : S185 - S185
[37] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
Schumann, C.
Paz-Ares, L.
Ciuleanu, T. -E
Lee, J. -S
Urban, L.
Caro, Bernabe R.
Park, K.
Sakai, H.
Ohe, Y.
Nishio, M.
Pluzanski, A.
Ramalingam, S. S.
Brahmer, J. R.
Borghaei, H.
O'Byrne, K. J.
Hellmann, M. D.
Memaj, A.
Bushong, J.
Tran, P.
Reck, M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 173 - 173
[38] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
Lei, Ming
Doki, Yuichiro
Kitagawa, Yuko
Kato, Ken
Chau, Ian
Yao, Jin
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Blum Murphy, Mariela A.
Novosiadly, Ruslan
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
[39] First-line (1L) treatment patterns in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (GC/GEJC/EAC): Data from the Spanish AGAMENON-SEOM registry
Jimenez-Fonseca, P.
Carmona-Bayonas, A.
Gallego Plazas, J.
Custodio, A.
Visa, L.
Martinez de Castro, E.
Gomez Gonzalez, L.
Moreno Gutierrez, M.
Polanco Sanchez, C.
Xiao, H.
ANNALS OF ONCOLOGY, 2022, 33 : S258 - S258
[40] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
Kato, K.
Xu, R-H.
Oh, D-Y.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Xu, H.
Sheng, T.
Barnes, G.
ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456

← 1 2 3 4 5 →